Imperial College Innovations Limited Portfolio Company Circassia Limited Achieves Key Phase II Clinical Development Milestone with Toleromune T-Cell Vaccine Technology for Treatment of Allergies
2/1/2011 9:35:56 AM
More...
|
Scientists Discover Way To Regulate The Body's Energy Expenditure
10/19/2005 5:11:37 PM
More...
|
Imperial College Innovations Limited Licenses T Cell Receptor (TCR) Therapy Technology To GANYMED Pharmaceuticals AG
10/19/2005 5:09:21 PM
More...
|